Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.


Founders Charles Weissmann Freimut Leidenberger Heinrich M. Schulte Karsten Henco Manfred Eigen Rudolf Rigler Ulrich Aldag


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 21
Average round size
The average size of a deal this fund participated in
Portfolio companies 18
Rounds per year 0.72
Lead investments 2
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Life Science

In 1993 was created Evotec, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Hamburg. The company was established in Europe in Germany.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this Corporate Investor is 6 percentage points less often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Evotec, startups are often financed by Tech Coast Angels, Frontier IP Group plc, CARB-X. The meaningful sponsors for the fund in investment in the same round are Alexandria Venture, venBio Partners, Woodford Investment Management. In the next rounds fund is usually obtained by GT Healthcare Capital Partners, Celgene, CARB-X.

This organization was formed by Manfred Eigen.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Artificial Intelligence. The fund has no exact preference in some founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Carrick Therapeutics, Eternygen, Forge Therapeutics

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
BeiChen Venture Capital Management Baoshan, China, Shanghai
Intelectium Ventures Community of Madrid, Madrid, Spain
Longwater Investment China, Shanghai
Silver Cloud Ventures Ltd. England, London, United Kingdom
Studio Hyperset California, Fremont, United States
Wedo Capital China, Wenzhou, Zhejiang
WHG Capital -
Xin Yu Li Mei -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Health Care
Life Science
$70M03 May 2022 Munich, Bavaria, Germany

Centauri Therapeutics

Health Care
$32M16 Feb 2022 United Kingdom, England, United Kingdom


Health Care
15 Feb 2022 Barcelona, Catalonia, Spain

Topas Therapeutics

Advanced Materials
Chemical Engineering
$21M29 Jul 2021 Germany, Baden-Württemberg, Germany


21 Apr 2021 Oxford, Oxfordshire, United Kingdom


Artificial Intelligence
Health Care
$40M04 Mar 2021 Oxford, England, United Kingdom


$59M02 Mar 2021 Paris, Ile-de-France, France

Blacksmith Medicines

Life Science
08 Jan 2021 San Diego, California, United States

Autobahn Labs

Life Science
24 Jun 2020 Palo Alto, California, United States
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Exscientia Closes $100M in Series C Financing

– Exscientia is a clinical stage pharmatech company pioneering the use of artificial intelligence (AI) to design new drugs.
– Company raised 100m in Series C funding.
– The round was led by BlackRock with participation from Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.
– The company intends to use the funds for platform development towards autonomous drug design, extension of its proprietary pipeline into clinical trials and expansion of existing capabilities in biological analytics that support target selection and portfolio development.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Evotec?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: